Lung cancer: KEYNOTE-001 — combo improves melody
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.85
Abstract: have become a treatment option for patients with non-small-cell lung cancer (NSCLC). Importantly, evidence from preclinical studies suggests that radiotherapy stimulates an antitumour immune response. In order to investigate this hypothesis, Percy Lee, Narek Shaverdian… read more here.
Keywords: trial; radiotherapy; months months; lung cancer ... See more keywords
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz011
Abstract: Abstract Background Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following… read more here.
Keywords: advanced melanoma; response; year; keynote 001 ... See more keywords